Transplantation of anergic histoincompatible bone marrow allografts

New England Journal of Medicine

Volumn 340, Issue 22, 1999, Pages 1704-1714

  Guinan, Eva C ^a,b   Boussiotis, Vassiliki A ^a   Neuberg, Donna ^a   Brennan, Lisa Lavita ^c   Hirano, Naoto ^a   Nadler, Lee M ^a   Gribben, John G ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA ANTIGEN CLASS 1; METHOTREXATE; METHYLPREDNISOLONE;

ADOLESCENT; ADULT; ALLOGRAFT; ANTIGEN PRESENTING CELL; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; CLONAL ANERGY; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HEMATOPOIESIS; HISTOCOMPATIBILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOPROPHYLAXIS; INFANT; MALE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADOLESCENT; ADULT; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; INFANT; LEUKEMIA; LYMPHOCYTE COUNT; LYMPHOMA; MALE; T-LYMPHOCYTES, HELPER-INDUCER; TISSUE DONORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 0033519661     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199906033402202     Document Type: Article

References (63)

1. Schwartz RS, Eisner A, Dameshek W. The effect of 6-mercaptopurine on primary and secondary immune responses. J Clin Invest 1959;38:1394-403.
2. Thomas ED, Collins JA, Herman EC Jr, Ferrebee JW. Marrow transplants in lethally irradiated dogs given methotrexate. Blood 1962;19:217-28.
3. Hitchings GH, Elion GB. Chemical suppression of the immune response. Pharmacol Rev 1963;15:365-405.
4. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998;338:1741-51.
5. Sullivan KM, Witherspoon RP, Storb R, et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 1988;72:555-61.
6. Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med 1976;84:304-15.
7. Bacigalupo A, Van Lint MT, Occhini D, et al. Increased risk of leukemia relapse with high-dose cyclosporinc A after allogeneic marrow transplantation for acute leukemia. Blood 1991;77:1423-8.
8. Weaver CH, Clift RA, Deeg HJ, et al. Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia. Bone Marrow Transplant 1994;14:885-93.
9. Craig FE, Gulley ML, Banks PM. Posttransplantation lymphoproliferative disorders. Am J Clin Pathol 1993;99:265-76.
10. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991;77: 1821-8.
11. Hanson MN, Morrison VA, Peterson BA, et al. Posttransplant T-cell lymphoproliferative disorders - an aggressive, late complication of solid-organ transplantation. Blood 1996;88:3626-33.
12. Penn I. Cancers following cyclosporine therapy. Transplantation 1987; 43:32-5.
13. Scott JP, Higenbottam TW. Adverse reactions and interactions of cyclosporin. Med Toxicol Adverse Drug Exp 1988;3:107-27.
14. Jenkins MK, Johnson JG. Molecules involved in T-cell costimulation. Curr Opin Immunol 1993;5:361-7.
15. Steinman RM, Young JW. Signals arising from antigen-presenting cells. Curr Opin Immunol 1991;3:361-72.
16. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science 1970;169:1042-9.
17. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992;71:1065-8.
18. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today 1994;15:321-32.
19. Bretscher P. The two-signal model of lymphocyte activation twenty-one years later. Immunol Today 1992;13:74-6.
20. Boussiotis VA, Gribben JG, Freeman GJ, Nadler LM. Blockade of the CD28 costimulatory pathway: a means to induce tolerance. Curr Opin Immunol 1994;6:797-807.
21. Lin H, Bolling SF, Linsley PS, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA-4Ig plus donor-specific transfusion. J Exp Med 1993;178:1801-6.
22. Lenschow DJ, Zeng Y, Thistlethwaite JR., et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA-4Ig Science 1992; 257:789-82.
23. Blazar BR, Taylor PA, Noelle RJ, Vallera DA. CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses. J Clin Invest 1998;102:473-82.
24. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 1997;94:8789-94.
25. Wagemaker G, Vriesendorp HM, van Bekkum DW. Successful bone marrow transplantation across major histocompatibility barriers in rhesus monkeys. Transplant Proc 1981;13:875-80.
26. Yunis EJ, Good RA, Smith J, Stutman O. Protection of lethally irradiated mice by spleen cells from neonatally thymectomized mice. Proc Natl Acad Sci U S A 1974;71:2544-8.
27. Reisner Y, Kapoor N, Kirkpatrick D, et al. Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 1983;61:341-8.
28. Korngold R, Sprent J. T cell subsets and graft-versus host-disease. Transplantation 1987;44:335-9.
29. Ferrara JLM, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324:667-74.
30. Martin PJ, Kernan NA. T-cell depletion for GVHD prevention in humans. In: Ferrara JLM, Decg HJ, Burakoff SJ, eds. Graft-vs.-host disease. 2nd ed. rev. New York: Marcel Dekker, 1997:615-37.
31. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174:561-9.
32. Gribben JG, Guinan EC, Boussiotis VA, et al. Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. Blood 1996;87:4887-93.
33. Guinan EC, Tarbell NJ, Tantravahi R, Weinstein HJ. Bone marrow transplantation for children with myelodysplastic syndromes. Blood 1989; 73:619-22.
34. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314:729-35.
35. Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997;97:855-64.
36. Meyers JD, Reed EC, Shepp DH, et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplanta-tion. N Engl J Med 1988;318:70-5.
37. Mitchell DM, Beverley PC, Boyle DG, Winger LA, Callard RE. Accessory cell and HLA compatibility requirements for the generation of specific in-vitro antibody responses to influenza virus by human blood lymphocytes. Immunology 1983;50:239-50.
38. Delgado JC, Clavijo OP, Yunis EJ. HLA class II allele typing is 100-fold more sensitive than class I in detecting chimerism states. Hum Immunol 1998;59:Suppl 1:106. abstract.
39. Provan D, Bartlett-Pandite L, Zwicky C, et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996;88:2228-35.
40. Andersen NS, Donovan JW, Boras JS, et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 1997;90:4212-21.
41. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989; 339:237-8. [Erratum, Nature 1989;339:490.]
42. Sullivan KM, Deeg HJ, Sanders J, et al. Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. Blood 1986;67:1172-5.
43. Anasetti C, Beatty PG, Storb R, et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia and lymphoma. Hum Immunol 1990;29: 79-91.
44. Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1983;313:765-7.
45. Beatty PG. Results of allogeneic bone marrow transplantation with unrelated or mismatched donors. Semin Oncol 1992;19:Suppl 7:13-9.
46. Gale RP, Bortin MM, van Bekkum DW, et al. Risk factors for acute graft-versus-host disesase. Br J Haematol 1987;67:397-406.
47. Sullivan KM. Graft-versus-host disease. In: Forman SJ, Blume KG, Thomas ED, eds. Bone marrow transplantation. Cambridge, Mass.: Blackwell Scientific, 1994:339-62.
48. Atkinson K, Farrelly H, Cooley M, O'Flaherty E, Downs K, Biggs J. Human marrow T cell dose correlates with severity of subsequent acute graft-versus-host disease. Bone Marrow-Transplant 1987;2:51-7.
49. Kernan NA, Collins NH, Juliano L, Cartagena T, Dupont B, O'Reilly RJ. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 1986;68:770-3.
50. Brass DS, Tutschka PJ, Farmer ER, et al. Predictive factors for acute graft-versus-host disease in patients transplanted with HLA-identical bone marrow. Blood 1984;63:1265-70.
51. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990;76:1867-71.
52. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-62.
53. Lazarus HM, Coccia PF, Herzig RH, et al. Incidence of acute graft-versus-host disease with and without methotrexate prophylaxis in allogeneic bone marrow transplant patients. Blood 1984;64:215-20.
54. Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cydosporine and methotrexate. Blood 1992;80:1838-45.
55. Weisdorf D, Hakke R, Blazer B, et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 1991;51:1197-203.
56. Powles RL, Morgenstern GR, Kay HEM, et al. Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet 1983;1:612-5.
57. Powles R, Pedrazzini A, Crofts M, et al. Mismatched family bone marrow transplantation. Semin Hematol 1984;21:182-7.
58. Munn RK, Henslee-Downey PJ, Romond EH, et al. Treatment of leukemia with partially matched related bone marrow transplantation. Bone Marrow Transplant 1997;19:421-7.
59. Henslee-Downey PJ, Abhyankar SH, Parrish RS, et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 1997;89:3864-72.
60. Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994;84:3948-55.
61. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998;339:1186-93.
62. Lamb LS Jr, Gee AP, Henslee-Downey PJ, et al. Phenotypic and functional reconstitution of peripheral blood lymphocytes following T cell-depleted bone marrow transplantation from partially mismatched related donors. Bone Marrow Transplant 1998;21:461-71.
63. Bozdech MJ, Sondel PM, Trigg ME, et al. Transplantation of HLA-haploidentical T-cell-depleted marrow for leukemia: addition of cytosine arabinoside to the pretransplant conditioning prevents rejection. Exp Hematol 1985;13:1201-10.